Full Press Release Details
Accessibility: Skip TopNav
DBV Technologies : Half year update on the DBV Technologies liquidity agreement
July 05, 2013 12:00 ET
DBV Technologies S.A.
DBV Technologies S.A.
Half year update on the DBV Technologies liquidity agreement
Bagneux, France, July 5, 2013 - Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on June 30th, 2013:
17,005 DBV TECHNOLOGIES shares
As a reminder, during the last half year liquidity agreement on December 31th, 2012, the following assets appeared on the liquidity account:
33,938 DBV TECHNOLOGIES shares
About DBV Technologies:
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people, constituting a major unmet medical need. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanuts, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure The product's clinically proven safety profile enables the application of effective desensitization techniques in the most severe forms of the allergy.
DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studies in Phase II program. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is a primary risk factors for childhood asthma.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com